Home > Healthcare IT > Myasthenia Gravis Treatment Market by Type, Treatment, End-User, Regional Outlook Insigh
Straits Research

Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market: Information by Type (Ocular MG, Congenital MG, Transient Neonatal MG), Treatment (Autologous HSCT, Surgery), End-User, Regional Outlook—Forecast Till 2026

Table of Content Download Sample

Market Snapshot

market snapshot
Base Year:
2017
Study Period:
2016-2026
CAGR:
12.1 %
Fastest Growing Market:
Asia Pacific
Largest Market:
North America

Global Statistics Representing Myasthenia Gravis Treatment Market Scenario

According to the Myasthenia Gravis Foundation of America, myasthenia gravis is one of the most common primary disorders of neuromuscular transmission. Around 14 to 20 out of every 100,000 people in the United States suffer from myasthenia gravis. While myasthenia gravis can affect people of all ages, it is more common in women under 40 and men older than 60. According to Elsevier, 1,283 New Zealanders are affected by a neuromuscular disorder, amounting to a collective prevalence of 30.25 cases per 100,000.

Growing development of novel drugs such as monoclonal antibodies is driving the growth of the myasthenia gravis treatment market. Moreover, growing awareness regarding treatment and increasing number of clinical facilities are also boosting market growth, globally.

The global myasthenia gravis treatment market was valued at around USD 1,011.1 million in 2017 and is expected to grow at a CAGR of 12.1% during the forecast period.

Intended Audience

  • Government Bodies
  • Hospitals & Clinics & Diagnostic Centres
  • Potential Investors
  • Research and Development Institutes
  • Healthcare Sectors

Segmental Insights

The global myasthenia gravis treatment market can be segmentation by type, treatment, end-user, and region. 

Based on type, the market can be segmented into ocular MG, congenital MG, and transient neonatal MG. The ocular MG segment is expected to account for a prominent market share, owing to the high prevalence of the disease.

Based on treatment, the market can be segmented into medication, surgery, Autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis & intravenous immunoglobulin, and others. Among these, the autologous hematopoietic stem cell transplantation segment is expected to hold a significant market share, owing to the therapy’s cost-effectiveness.

Based on end-user, the market can be segmented into hospitals, clinics, academic research institutes, and others. Among these, the hospitals segment is expected to hold a noteworthy market share during the forecast period.

Regional Analysis

The global myasthenia gravis treatment market has been classified into four key regions, namely North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is expected to hold the largest market share, owing to the increasing number of drug manufacturers and rising awareness about the long-term effects of muscular dystrophy. Moreover, increasing government funding for the treatment of this disease in North America is also favoring market growth. According to National Centers for Advancing Translation Science, in the U.S., around 1 in 500,000 people suffer from disorders each year.

Asia Pacific is expected to be the fastest growing region due to the increasing awareness about neuromuscular disorders and enhancement in healthcare reforms across countries such as Malaysia, India, Indonesia, and China. Apart from this, the increasing geriatric population is supporting market growth on account of the increasing prevalence of the disorder.

Europe accounts for the second largest share in the myasthenia gravis treatment market, owing to the increasing prevalence of autoimmune disorders in the region. For instance, As per Muscular Dystrophy UK, about 15 in every 100,000 people in the U.K. are affected by myasthenia gravis.

The Middle East region is projected to witness steady growth, owing to the extensive advancement of healthcare infrastructure and growing R&D activities in the healthcare sector.

Key Developments

  • In 2018, Teva Pharmaceutical Industries Ltd. launched the generic version of Syprine capsules, 250 mg, in the U.S.
  • In 2015, Fresenius Kabi introduced the anti-infective Moxifloxacin Injection 400 mg per 250 mL in Freeflex bags.

Report Inclusions

  • Historical inferences, findings & analysis of the market for the duration of 2016 to 2018
  • Projections and performance forecast analysis for the duration of 2019 to 2026
  • Production and consumption point-of-view (POV) analysis
  • Market driver, restraint and opportunity analysis to define market dynamics, covering industry, regulatory, innovation, technological, and pricing trends
  • Comprehensive competitive landscape mapping with recent developments, covering market leadership, competency, sustainability, and future prospects

Key Players

Some of the key players in the global myasthenia gravis treatment market are Valeant Pharmaceuticals International, Novartis Pharmaceuticals Corporation, Apotex Corporation, Teva Pharmaceutical Industries Ltd., RPG Life Sciences, Cipla, F. Hoffmann Roche La Ltd., Bristol-Myers Squibb Company, Biogen Inc., AbbVie Inc., GlaxoSmithKline plc, and Fresenius Kabi.

Report Scope

Report Metric Details
Market Size USD 1,011.1 million in 2017
CAGR CAGR 12.1%
Historical Data 2015-2016
Base Year 2017
Forecast Period 2018-2026
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Type (Ocular MG, Congenital MG, Transient Neonatal MG), Treatment (Autologous HSCT, Surgery), End-User
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Valeant Pharmaceuticals International, Novartis Pharmaceuticals Corporation, Apotex Corporation, Teva Pharmaceutical Industries Ltd., RPG Life Sciences, Cipla, F. Hoffmann Roche La Ltd., Bristol-Myers Squibb Company, Biogen Inc., AbbVie Inc., GlaxoSmithKline plc, and Fresenius Kabi.,
Key Market Opportunities High Demand In Healthcare It Sector Is Pushing Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market Segmentation

By Type

  • Ocular MG
  • Congenital MG
  • Transient Neonatal MG

By Treatment

  • Medication
  • Surgery
  • Autologous Hematopoietic Stem Cell Transplantation (HSCT)
  • Plasmapheresis & Intravenous Immunoglobulin
  • Others

By End-User

  • Hospitals
  • Clinics
  • Academic Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Price Starts From
USD4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Johnson & Johnson
Need Assistance?
+1 646 480 7505 (U.S.)
+44 208 068 9665 (U.K.)
Looking For Custom Report ?

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Check Our License Options :
Report Snapshot

As featured on :

clients
Trusted by Fortune 500
Over 30000+ subscribers